Pfizer's Litfulo meets Phase 3 goals in vitiligo skin condition

July 30, 2026 6:45 AM

Pfizer Inc. (NYSE: PFE) announced positive topline results from two Phase 3 trials evaluating its oral drug Litfulo (ritlecitinib) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found